Craniopharyngioma cell growth is promoted by growth hormone (GH) and is inhibited by tamoxifen: Involvement of growth hormone receptor (GHR) and IGF-1 receptor (IGF-1R)-Reference-Cited by-同舟云学术

Craniopharyngioma cell growth is promoted by growth hormone (GH) and is inhibited by tamoxifen: Involvement of growth hormone receptor (GHR) and IGF-1 receptor (IGF-1R)

Published:2013-01 Issue:1 Volume:20 Page:153-157
ISSN:0967-5868
Container-title:Journal of Clinical Neuroscience
language:en
Short-container-title:Journal of Clinical Neuroscience

Author:

Li Qiang,You Chao,Liu Liang,Rao Zhengxi,Sima Xiutian,Zhou Liangxue,Xu Jianguo

Publisher

Elsevier BV

Subject

Physiology (medical),Clinical Neurology,Neurology,General Medicine,Surgery

Reference19 articles.

1. Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database);Geffner;J Clin Endocrinol Metab,2004

2. Hormone receptor expression in craniopharyngiomas: a clinicopathological correlation;Hofmann;Neurosurgery,2010

3. Inhibitory action on GHRH-induced GH secretion of chronic tamoxifen treatment in breast cancer;De Marinis;Clin Endocrinol (Oxf),2000

4. Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach;Ulfarsson;Clin Cancer Res,2005

5. Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling;Holsken;Acta Neuropathol,2010

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Collision Tumor of Pit-1/SF-1-positive Double Pituitary Adenoma and a Craniopharyngioma Coexisting with Graves' Disease;NMC Case Report Journal;2023-12-31

2. Safety of Growth Hormone Replacement Therapy in Childhood-Onset Craniopharyngioma: A Systematic Review and Cohort Study;Neuroendocrinology;2023-05-25

3. Predictive Factors for Pediatric Craniopharyngioma Recurrence: An Extensive Narrative Review;Diagnostics;2023-04-28

4. Benefits and risks evaluation of recombinant human growth hormone replacement therapy in children with GHD after craniopharyngioma surgery;Journal of Pediatric Endocrinology and Metabolism;2023-03-21

5. GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?;The Journal of Clinical Endocrinology & Metabolism;2023-02-16